Tompkins Financial Corp Lowers Stock Position in Eli Lilly and Company $LLY

Tompkins Financial Corp trimmed its stake in Eli Lilly and Company (NYSE:LLY) by 3.8% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 29,128 shares of the company’s stock after selling 1,161 shares during the quarter. Eli Lilly and Company makes up 2.4% of Tompkins Financial Corp’s holdings, making the stock its 9th biggest position. Tompkins Financial Corp’s holdings in Eli Lilly and Company were worth $31,303,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds also recently modified their holdings of the stock. Vanguard Group Inc. increased its position in Eli Lilly and Company by 0.7% in the third quarter. Vanguard Group Inc. now owns 80,959,089 shares of the company’s stock worth $61,771,785,000 after buying an additional 551,659 shares during the last quarter. State Street Corp grew its stake in shares of Eli Lilly and Company by 0.6% during the 3rd quarter. State Street Corp now owns 34,726,558 shares of the company’s stock worth $26,496,364,000 after acquiring an additional 219,590 shares during the period. Capital Research Global Investors grew its stake in shares of Eli Lilly and Company by 20.9% during the 3rd quarter. Capital Research Global Investors now owns 25,088,371 shares of the company’s stock worth $19,141,787,000 after acquiring an additional 4,332,008 shares during the period. Wellington Management Group LLP increased its holdings in Eli Lilly and Company by 4.1% in the 3rd quarter. Wellington Management Group LLP now owns 14,563,780 shares of the company’s stock worth $11,112,164,000 after acquiring an additional 574,229 shares during the last quarter. Finally, Laurel Wealth Advisors LLC increased its holdings in Eli Lilly and Company by 78,621.2% in the 2nd quarter. Laurel Wealth Advisors LLC now owns 11,552,336 shares of the company’s stock worth $9,005,392,000 after acquiring an additional 11,537,661 shares during the last quarter. Institutional investors own 82.53% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts have commented on the stock. BMO Capital Markets reaffirmed an “outperform” rating and set a $1,300.00 price objective on shares of Eli Lilly and Company in a report on Thursday, February 5th. Barclays began coverage on shares of Eli Lilly and Company in a research report on Thursday, February 19th. They issued an “overweight” rating and a $1,350.00 price target on the stock. CICC Research upped their price target on shares of Eli Lilly and Company from $1,060.00 to $1,107.00 and gave the company a “neutral” rating in a research note on Wednesday, February 11th. Morgan Stanley reaffirmed an “overweight” rating and issued a $1,313.00 price objective on shares of Eli Lilly and Company in a report on Thursday, March 5th. Finally, Royal Bank Of Canada assumed coverage on shares of Eli Lilly and Company in a report on Tuesday, February 24th. They set an “outperform” rating and a $1,250.00 target price on the stock. Two research analysts have rated the stock with a Strong Buy rating, twenty-three have given a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Eli Lilly and Company presently has an average rating of “Moderate Buy” and a consensus price target of $1,221.44.

Eli Lilly and Company Price Performance

LLY stock opened at $902.00 on Wednesday. The company has a debt-to-equity ratio of 1.54, a current ratio of 1.58 and a quick ratio of 1.19. Eli Lilly and Company has a one year low of $623.78 and a one year high of $1,133.95. The stock has a market cap of $852.23 billion, a PE ratio of 39.30, a P/E/G ratio of 1.06 and a beta of 0.40. The firm has a 50 day simple moving average of $1,016.28 and a two-hundred day simple moving average of $961.72.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings data on Wednesday, February 4th. The company reported $7.54 earnings per share for the quarter, beating the consensus estimate of $7.48 by $0.06. Eli Lilly and Company had a net margin of 31.66% and a return on equity of 102.94%. The firm had revenue of $19.29 billion for the quarter, compared to analysts’ expectations of $17.85 billion. During the same quarter last year, the company posted $5.32 EPS. The business’s quarterly revenue was up 42.6% on a year-over-year basis. Eli Lilly and Company has set its FY 2026 guidance at 33.500-35.000 EPS. On average, analysts predict that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Key Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Morgan Stanley reiterated an Overweight rating and a $1,313 price target, citing growth potential from Lilly’s new employer access platform for obesity therapies — a key commercial lever for Zepbound and related products. Morgan Stanley Reiterates Overweight on Eli Lilly (LLY), Cites Growth Potential of New Platform
• Positive Sentiment: Lilly reported completing a pediatric PK study for a next‑gen diabetes candidate — a near-term clinical milestone that de‑risks development and supports longer-term diabetes franchise growth. Lilly Advances Next-Gen Diabetes Drug With Completed Pediatric PK Study
• Positive Sentiment: Retail distribution for Zepbound expanded as Kroger pharmacies began offering the weight‑management medication with support/savings programs — incremental access that can materially boost prescriptions and uptake. What Kroger (KR)’s New Zepbound Access and Premium Ice Cream Push Means For Shareholders
• Positive Sentiment: Profile-raising coverage: analysts and outlets continue to highlight significant upside based on Lilly’s recent quarterly beat and robust FY26 guidance, supporting conviction among buy‑and‑hold investors. Here’s How Much Upside Eli Lilly Stock Has, According to Analysts
• Neutral Sentiment: STAT profiles Jacob van Naarden and his role in pushing Lilly’s oncology strategy after Loxo — signals deeper focus on cancer pipeline expansion but with long timelines to commercialization. How an outsider crept into Eli Lilly’s top ranks — and plans to drive its business forward
• Neutral Sentiment: Attendance at the China Development Forum signals Lilly’s intent to pursue growth in China — positive strategic positioning but geopolitics keeps the opportunity uncertain. U.S. executives, from Apple to Eli Lilly, revamp their push into the world’s second-largest economy at the China Development Forum
• Neutral Sentiment: Market commentary offers defensive options (buy‑the‑dip ETF exposure) and reminders that LLY has pulled back after a multi‑year run — investor positioning may be shifting to diversified healthcare exposure. Want to Buy the Dip on Eli Lilly? Consider This Low-Cost Vanguard ETF
• Negative Sentiment: Lilly will phase out select insulin products across Europe by 2027 — could reduce sales or create transitional market disruption in a large region. Eli Lilly to phase out select insulin products across Europe by 2027
• Negative Sentiment: Local scrutiny and planning pushback around a large new Lilly plant (LVPC review, traffic concerns, community hearings) may delay timelines and increase project costs. Massive Eli Lilly project goes under LVPC microscope
• Negative Sentiment: Legal overhang: coverage notes the U.S. Supreme Court revived Actos litigation risk, a reminder litigation exposure can create headline-driven volatility. What’s Going On With Eli Lilly On Monday?

Eli Lilly and Company Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.